About OnyvaxSciencePress ReleasesClinical TrialsCareersContact
Onyvax - oncology vaccines 

Media Coverage

Current Press Releases

Archived Press Releases

Press Releases image

Archived Press Releases

May 11, 1999

Onyvax Licenses Anti-cancer Vaccine from Cancer Research Campaign Technology

Onyvax Limited (London, UK; http://www.onyvax.com) and Cancer Research Campaign Technology Limited (CRCT) have signed an agreement granting Onyvax exclusive world-wide rights to develop the anti-cancer vaccine, 105AD7. Onyvax will initially evaluate the vaccine as a treatment for colorectal cancer for which clinical trials will commence in the next twelve months. The vaccine may also be evaluated in a range of other tumour types. The financial terms of the agreement have not been disclosed but include an upfront payment, development milestones and royalties paid to CRCT.

Onyvax is an early stage biotechnology company focussed on the research and development of vaccines and other therapies which will direct the immune system to attack cancer cells. Anthony Walker, Chief Executive of Onyvax said "105AD7 is an exciting opportunity to develop a technology that is highly complementary to Onyvax's existing cancer immunotherapy programmes. If successful in clinical trials, this product will address significant unmet medical needs in a number of major cancer types".

The vaccine, 105AD7, was developed by Dr Linda Durrant at the University of Nottingham funded by the Cancer Research Campaign. The vaccine is based on an antibody which mimics a naturally occurring molecule called Decay Accelerating Factor (DAF, CD55) which is present and often over expressed in a range of cancers including colorectal and ovarian. The vaccine works by generating a potent immune response against DAF resulting in the selective killing of cancerous cells. The 105AD7 antibody is covered by a granted European patent and is the subject of a US patent application.

Back to Archived Releases Back to Archived Releases

© 1998-2009 Onyvax Ltd. All Rights Reserved